Publications by authors named "I Madelaine-Chambrin"
Brentuximab vedotin (BV)-bendamustine (90 or 120 mg/m2 day 1 and 2) every 28 days is an effective treatment for relapsed/refractory Hodgkin lymphoma (R/R HL) but associated to high toxicity especially for elderly patients. We conducted in St Louis Hospital, Paris, between 2015 and 2021 a retrospective single-center analysis of 44 patients with R/R HL treated with one-day BV-bendamustine (120 mg/m2) every 21 days. Sixteen percent of patients were ≥ 60 years old (yo).
View Article and Find Full Text PDFObjectives: We sought to estimate the prevalence of patients with cancer presenting to the emergency department (ED) who are undergoing treatment with immune checkpoint blockade (ICB) therapy; report their chief complaints; describe and estimate the prevalence of immune-related adverse events (IRAEs).
Methods: Four abstractors reviewed the medical records of patients with cancer treated with ICB who presented to an ED in Paris, France between January 2012 and June 2017. Chief complaints, underlying malignancy and ICB characteristics, and the final diagnoses according to the emergency physician were recorded.
Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.
Cancer Immunol Immunother
August 2018
Article Synopsis
- Anti-PD-1 and anti-CTLA-4 antibody treatments for melanoma can lead to autoimmune side effects, including type 1 diabetes (T1D), through increased production of certain cytokines.
- A study at Saint Louis Hospital from 2014 to 2016 found 3 cases of T1D among 132 melanoma patients treated with anti-PD-1, while blood glucose levels remained stable but C-reactive protein (CRP) significantly rose.
- Data from the French Pharmacovigilance Database also revealed 14 rapid and severe T1D cases during immunotherapy, suggesting that anti-PD-1 treatment is associated with increasing CRP levels, which may lead to insulin resistance without immediate impact on
Article Synopsis
- Advances in targeted therapy and immune checkpoint inhibitors, like cobimetinib and vemurafenib, have improved the prognosis for melanoma patients, particularly those with BRAF mutations.
- A case study highlighted a serious side effect of cobimetinib: focal necrotizing myopathy with symptoms such as severe neck weakness and elevated creatine phosphokinase (CPK) levels, confirmed by muscle biopsy.
- After temporarily stopping cobimetinib and normalizing CPK levels, the patient showed a partial response, leading to a continued but reduced dosage of the therapy, emphasizing the importance of being aware of potential adverse effects in future treatments.
Article Synopsis
- Anti-PD-1 antibody treatment is effective for advanced melanoma, improving survival rates but comes with significant immune-related side effects like rash and thyroiditis.
- A case study highlighted a 73-year-old man who developed autoimmune diabetes following nivolumab treatment, leading to diabetic ketoacidosis six weeks in.
- Investigations showed pre-existing islet cell autoantibodies, indicating a potential autoimmune reaction triggered by the medication, suggesting that glucose levels should be closely monitored in patients on PD-1 blockade.